Lotta Vassilev

721 total citations
13 papers, 322 citations indexed

About

Lotta Vassilev is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, Lotta Vassilev has authored 13 papers receiving a total of 322 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 10 papers in Genetics and 8 papers in Molecular Biology. Recurrent topics in Lotta Vassilev's work include Virus-based gene therapy research (10 papers), CAR-T cell therapy research (9 papers) and Viral Infectious Diseases and Gene Expression in Insects (8 papers). Lotta Vassilev is often cited by papers focused on Virus-based gene therapy research (10 papers), CAR-T cell therapy research (9 papers) and Viral Infectious Diseases and Gene Expression in Insects (8 papers). Lotta Vassilev collaborates with scholars based in Finland, United Kingdom and Switzerland. Lotta Vassilev's co-authors include Akseli Hemminki, Vincenzo Cerullo, Anna Kanerva, Simona Bramante, Sari Pesonen, Anniina Koski, Timo Joensuu, Minna Oksanen, Mari Hirvinen and Ilkka Liikanen and has published in prestigious journals such as PLoS ONE, International Journal of Cancer and Molecular Therapy.

In The Last Decade

Lotta Vassilev

12 papers receiving 318 citations

Peers

Countries citing papers authored by Lotta Vassilev

Since Specialization

Citations

This map shows the geographic impact of Lotta Vassilev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lotta Vassilev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lotta Vassilev more than expected).

Fields of papers citing papers by Lotta Vassilev

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lotta Vassilev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lotta Vassilev. The network helps show where Lotta Vassilev may publish in the future.

Co-authorship network of co-authors of Lotta Vassilev

This figure shows the co-authorship network connecting the top 25 collaborators of Lotta Vassilev. A scholar is included among the top collaborators of Lotta Vassilev based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lotta Vassilev. Lotta Vassilev is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Real-world Evidence of Multiple Myeloma Treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland 2023 ·Future Oncology ·(unknown), Kristiina Uusi-Rauva, Tuuli Ranki, Iiro Toppila, (unknown), (unknown), Lotta Vassilev, Kimmo Porkka, Raija Silvennoinen, Oscar Brück	2
2	Retrospective, Registry-based, Cohort Investigation of Clinical Outcomes in Patients with Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma in Finland 2022 ·Acta Dermato Venereologica ·Samuli Tuominen, Liisa Ukkola‐Vuoti, Pilvi Riihilä, (unknown), Veli‐Matti Kähäri, Mariann I. Lassenius, Tuuli Ranki, (unknown), Lotta Vassilev, S. Vuoti, Kalle Mattila	1
3	Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 – Support for clinical studies on advanced cancer treatment 2017 ·PLoS ONE ·Łukasz Kuryk, Lotta Vassilev, Tuuli Ranki, Akseli Hemminki, Aila Karioja‐Kallio, (unknown), (unknown), Vincenzo Cerullo, Sari Pesonen	32
4	661. Synergistic Anti-Tumor Efficacy of Immunogenic Adenovirus ONCOS-102 and Standard of Care Chemotherapy in Preclinical Mesothelioma Model 2016 ·Molecular Therapy ·Łukasz Kuryk, Elina Haavisto, Mariangela Garofalo, Cristian Capasso, Mari Hirvinen, Sari Pesonen, Tuuli Ranki, Lotta Vassilev, Vincenzo Cerullo	3
5	Synergistic anti‐tumor efficacy of immunogenic adenovirus ONCOS‐102 (Ad5/3‐D24‐GM‐CSF) and standard of care chemotherapy in preclinical mesothelioma model 2016 ·International Journal of Cancer ·Łukasz Kuryk, Elina Haavisto, Mariangela Garofalo, Cristian Capasso, Mari Hirvinen, Sari Pesonen, Tuuli Ranki, Lotta Vassilev, Vincenzo Cerullo	45
6	Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy 2016 ·OncoImmunology ·Sadia Zafar, Suvi Parviainen, Mikko Siurala, Otto Hemminki, Riikka Havunen, Siri Tähtinen, Simona Bramante, Lotta Vassilev, Hongjie Wang, André Lieber, Silvio Hemmi, Tanja D. de Gruijl, Anna Kanerva, Akseli Hemminki	26
7	Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer 2015 ·OncoImmunology ·Simona Bramante, Anniina Koski, Ilkka Liikanen, Lotta Vassilev, Minna Oksanen, Mikko Siurala, Raita Heiskanen, Tiina Hakonen, Timo Joensuu, Anna Kanerva, Sari Pesonen, Akseli Hemminki	36
8	Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues 2015 ·Molecular Therapy ·Anniina Koski, Simona Bramante, Anja Kipar, Minna Oksanen, Juuso Juhila, Lotta Vassilev, Timo Joensuu, Anna Kanerva, Akseli Hemminki	24
9	Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus 2015 ·Molecular Therapy ·(unknown), Ilkka Liikanen, Juuso Juhila, Riku Turkki, Siri Tähtinen, Matti Kankainen, Lotta Vassilev, Ari Ristimäki, Anniina Koski, Anna Kanerva, Iulia Diaconu, Vincenzo Cerullo, Markus Vähä‐Koskela, Minna Oksanen, Nina Linder, Timo Joensuu, Johan Lundin, Akseli Hemminki	25
10	Abstract B51: Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans 2015 ·Cancer Immunology Research ·Simona Bramante, Johanna K. Kaufmann, Ville Veckman, Dirk M. Nettelbeck, Otto Hemminki, Ilkka Liikanen, Lotta Vassilev, Vincenzo Cerullo, Minna Oksanen, Raita Heiskanen, Timo Joensuu, Anna Kanerva, Sari Pesonen, Markus Vähä‐Koskela, Anniina Koski, Akseli Hemminki	0
11	Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM‐CSF: Results in vitro, in rodents and in humans 2015 ·International Journal of Cancer ·Simona Bramante, Johanna K. Kaufmann, Ville Veckman, Ilkka Liikanen, Dirk M. Nettelbeck, Otto Hemminki, Lotta Vassilev, Vincenzo Cerullo, Minna Oksanen, Raita Heiskanen, Timo Joensuu, Anna Kanerva, Sari Pesonen, Sampsa Matikainen, Markus Vähä‐Koskela, Anniina Koski, Akseli Hemminki	41
12	Oncolytic adenovirus and doxorubicin‐based chemotherapy results in synergistic antitumor activity against soft‐tissue sarcoma 2014 ·International Journal of Cancer ·Mikko Siurala, Simona Bramante, Lotta Vassilev, Mari Hirvinen, Suvi Parviainen, Siri Tähtinen, Kilian Guse, Vincenzo Cerullo, Anna Kanerva, Anja Kipar, Markus Vähä‐Koskela, Akseli Hemminki	50
13	Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans 2013 ·International Journal of Cancer ·Simona Bramante, Anniina Koski, Anja Kipar, Iulia Diaconu, Ilkka Liikanen, Otto Hemminki, Lotta Vassilev, Suvi Parviainen, Vincenzo Cerullo, Saila K. Pesonen, Minna Oksanen, Raita Heiskanen, (unknown), (unknown), Tiina Hakonen, Timo Joensuu, Anna Kanerva, Sari Pesonen, Akseli Hemminki	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact